The Access to Excellent Care for Sickle Cell Patients (ACCEL) is a grant awarded to institutions and healthcare organizations for programs with a focus on patient access to care, supporting SCD clinics and transition of care from pediatric to adult.
Donor Name: Global Blood Therapeutics (GBT) Foundation
State: All States
County: All Counties
Type of Grant: Grant
Deadline (mm/dd/yyyy): 07/29/2022
Grant Size: up to $100,000
Grant Duration: 12 months
Details:
Grants will be awarded to organizations seeking to provide innovative and sustainable health care solutions that support SCD patients, caregivers and the overall SCD community.
Suggested Access to Excellent Care for Sickle Cell Patients programs may include, but are not limited to:
- Transition of Care: Pediatric to adult care
- Innovative Patient Access to Care Models
- Building innovative SCD clinics
Funding Information
- Up to five proposals of up to $100,000 will be funded, for a total of up to $500,000.
- The funding period is 12 months from the date of award.
Eligibility Criteria
To be considered for support, applicants must:
- Be a U.S.-based nonprofit organization dedicated to Sickle Cell and are exempt from taxation under section 501(c)(3) of the Internal Revenue Code. Proof of tax-exempt status will be required.
- Specific to community-based organizations, and not institutions.
- Have the organizational capacity needed to manage the proposed project’s timeline and deliverables.
- Only one grant proposal application per organization will be considered.
- Previous ACCEL awardees may apply, but preference will be given to new program initiatives.
